Pravin U. Dugel, MD
Show Description +
Pravin U. Dugel, MD, reviews recent clinical trial data concerning three new drugs: brolucizumab (formerly RTH258, Novartis), a humanized single-chain antibody fragment; faricimab (formerly RG7716, Genentech), the first bispecific antibody designed for intraocular use; and RGX-314 (REGENEXBIO), a one-time subretinal treatment for wet age-related macular degeneration.
Posted: 9/22/2018
Pravin U. Dugel, MD
Pravin U. Dugel, MD, reviews recent clinical trial data concerning three new drugs: brolucizumab (formerly RTH258, Novartis), a humanized single-chain antibody fragment; faricimab (formerly RG7716, Genentech), the first bispecific antibody designed for intraocular use; and RGX-314 (REGENEXBIO), a one-time subretinal treatment for wet age-related macular degeneration.
Posted: 9/22/2018
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of EURETINA: 2018.
Please log in to leave a comment.